glp-1 hypertension Cardiovascular Protective Properties of Receptor Agonists: More than Just Diabetic and Weight Loss Drugs Cardiovascular disease continuum-GLP-1 action. Adapted

In 2019, for example, researchers conducted a randomized, double-blind, and placebo-controlled experiment on 60 participants over 60 days

Dose optimization, lifestyle reinforcement, or switching to a dual-agonist like tirzepatide typically restarts results

The result: Increased glucose-dependent insulin secretion Reduced glucagon release Better control of fasting & postprandial glucose Weight-neutral therapy with minimal risk of hypoglycemia A simple yet effective mechanism that plays a powerful role in modern diabetes management

Accordingly, early pharmacological intervention provides a pragmatic solution to the limitations of behavioral therapy alone

Letelier et al